Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus

The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.

Study Overview

• Status: Completed
• Conditions: Glucose Metabolism Disorders; Metabolic Diseases; Diabetes Mellitus, Type 2; Diabetes Mellitus; Endocrine System Diseases
• Intervention / Treatment: Biological: Placebo; Biological: Placebo; Biological: PF-04856883; Biological: PF-04856883

• Study Type: Interventional
• Enrollment (Actual): 84
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Chula Vista, California, United States, 91911
      • Profil Institute for Clinical Research, Inc.
  • Florida
    • Miami, Florida, United States, 33169
      • Elite Research Institute
    • Miramar, Florida, United States, 33025
      • Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • Atlanta Center for Medical Research
  • Nebraska
    • Omaha, Nebraska, United States, 68154
      • ICON Clinical Pharmacology, LLC
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19139
      • CRI Worldwide, LLC
  • Texas
    • San Antonio, Texas, United States, 78209
      • Healthcare Discoveries LLC d/b/a ICON Development Solutions

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• History of Type 2 diabetes and currently being treated with high dose metformin
• BMI between 22.0 and 40.0 kg/m2
• HbA1c between 7.0-10.0%
• Fasting C-peptide >1.21 ng/mL

Exclusion Criteria:

• History of clinically significant chronic conditions other than Type 2 diabetes not well controlled by either diet or medications
• Treatment with anti-diabetic therapies other than metformin
• History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody
• Males or women of childbearing potential

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

13

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Treatment Arm 1 (Stage 1A)	Biological: Placebo; Single subcutaneous injection of placebo; Biological: Placebo; Multiple weekly subcutaneous injections of placebo for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 2 (Stage 1A)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 3 (Stage 1A)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 4 (Stage 1A)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Placebo Comparator: Treatment Arm 5 (Stage 1B)	Biological: Placebo; Single subcutaneous injection of placebo; Biological: Placebo; Multiple weekly subcutaneous injections of placebo for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 6 (Stage 1B)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 7 (Stage 1B)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 8 (Stage 1B)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Placebo Comparator: Treatment Arm 9 (Stage 2)	Biological: Placebo; Single subcutaneous injection of placebo; Biological: Placebo; Multiple weekly subcutaneous injections of placebo for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 10 (Stage 2)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 11 (Stage 2)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 12 (Stage 2)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096
Experimental: Treatment Arm 13 (Stage 2)	Biological: PF-04856883; Single subcutaneous injection of PF-04856883; Other Names: CVX-096; Biological: PF-04856883; Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks; Other Names: CVX-096

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose (Day 50) that were absent before treatment or that worsened relative to pretreatment state.	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50
Number of Participants With Clinically Significant Physical Examination Findings	Physical examination included examination of general appearance, head, ears, eyes (including fundoscopy), nose, mouth, throat, neck (including thyroid), skin, breast (optional), cardiac, respiratory, gastrointestinal, musculoskeletal and neurological systems.	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)	ECG parameters included pulse rate (PR) interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria of clinically significant concern were 1) PR interval: greater than equal to (>=) 25 percent (%) increase when baseline greater than (>)200 milliseconds (msec); or increase >=50% when baseline less than or equal to (<=200) msec; 2) QRS interval: >=25% increase when baseline >100 msec; >=50% increase when baseline <= 100 msec; 3) QTCF interval: QTc interval using Fridericia's formula (QTcF interval) and Bazett's formula (QTcB interval): absolute value 450 - <480 msec, 480 - <500 msec >=500; absolute change 30 - <60, >=60 msec. The number of participants with potentially clinically significant ECG findings at any visit were reported. IFB = increase from baseline.	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50
Number of Participants With Vital Sign Abnormalities	Criteria for vital signs abnormalities: sitting/supine systolic pulse rate less than (<) 40 beats per minute (bpm) or greater than (>) 120 bpm, standing/supine systolic pulse < 40 bpm or > 140 bpm, systolic blood pressure of >=30 millimeters of mercury (mmHg) change from baseline and systolic blood pressure <90 mmHg, diastolic blood pressure >=20 mmHg change from baseline and diastolic blood pressure <50 mm Hg.	Stage 1: Baseline up to Day 29; Stage 2 : Baseline up to Day 50
Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements	Following parameters were analyzed for laboratory examination: Hematology: hemoglobin, hematocrit, red blood cell (RBC) <0.8*lower limit of the reference range (LLRR); leukocytes <0.6*LLRR or >1.5*ULRR; platelet count <0.5*LLRR or >1.75*upper limit of the reference range (ULRR); total neutrophils (absolute [abs]), lymphocytes (abs) <0.8*LLRR or >1.2*ULRR; eosinophils (abs), basophils (abs), monocytes (abs) >1.2*ULRR; chemistry (total bilirubin, direct bilirubin, indirect bilirubin >1.5*ULRR; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase >3*ULRR, albumin, total protein <0.8*LLRR or >1.2*ULRR; blood urea nitrogen (BUN), creatinine >1.3*ULRR; glucose (fasting) <0.6*LLRR or >1.5*ULRR; uric acid >1.2* ULRR; sodium <0.95*LLRR or >1.05*ULRR; potassium, chloride, bicarbonate, calcium <0.9*LLRR or >1.1*ULRR. Urinalysis: Urine white blood cell (WBC), Urine RBC =>20/ high-power field (HPF).	Stage 1: Baseline up to Day 29; Stage 2: Baseline up to Day 50

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 1		predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1
Maximum Observed Plasma Concentration (Cmax) of PF-04856883: Stage 2		predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 1		predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883: Stage 2		predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336 hours postdose on Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) of PF-04856883: Stage 1	AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1
Area Under the Concentration Time Curve From Time Zero to Time Tau (AUCtau) of PF-04856883: Stage 2	Area under the serum concentration-time curve from time 0 to tau (AUCtau), where tau was the dosing interval of 168 hours.	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168 hours postdose Day 1; predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168 hours postdose Day 22
Apparent Clearance (CL/F) of PF-04856883: Stage 1	It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 1 only.	predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1
Apparent Clearance (CL/F) of PF-04856883: Stage 2	It was calculated by dividing dose with AUC (0 - ∞) where AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). Outcome measure was planned to be analyzed in Stage 2 only. Data was not estimable if values were below the limit of quantification.	predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22
Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 1		predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1
Apparent Volume of Distribution (Vz/F) of PF-04856883: Stage 2		predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22
Terminal Elimination Half- Life (t1/2) of PF-04856883: Stage 1		predose (0 hour), 1, 6, 12, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 1
Terminal Elimination Half-life (t1/2) of PF-04856883: Stage 2		predose (0 hour), 1, 2, 6, 24, 48, 72, 120, 168, 336, 504, 672 hours postdose on Day 22
Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC	Baseline, Day 3 and 8
Change From Baseline in Post-prandial Glucose Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.	Baseline, Day 3, 15, 24, 29 and 50
Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.	Baseline, Day 3 and 8
Change From Baseline in Insulin Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.	Baseline, Day 3, 15, 24, 29 and 50
Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3 and 8: Stage 1	Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.	Baseline, Day 3 and 8
Change From Baseline in C-Peptide Area Under the Curve (AUC) After Mixed Meal Tolerance Test (MMTT) at Day 3, 15, 24, 29 and 50: Stage 2	Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.	Baseline, Day 3, 15, 24, 29 and 50
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 15, 22 and 29: Stage 1		Baseline, Day 2, 4, 6, 15, 22 and 29
Change From Baseline in Fasting Plasma Glucose (FPG) at Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43: Stage 2		Baseline, Day 2, 4, 6, 8, 22, 23, 25, 27, 30, 36 and 43
Change From Baseline in 24 Hours Glucose Normalized Area Under the Curve (NAUC) Profile at Day 30: Stage 2	A normalized area under the curve (NAUC) were computed by dividing the AUC by the amount of time between the last time point captured and the first time point captured.	Baseline, Day 30
Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 29 and 50: Stage 2	HbA1c is a measure of the glycosylated hemoglobin. Change (measured as percent): HbA1c at observation minus HbA1c at baseline. Outcome measure was planned to analyzed only for Stage 2.	Baseline, Day 29 and 50
Change From Baseline in Fructosamine Levels at Day 8, 15 and 29: Stage 1		Baseline, Day 8, 15 and 29
Change From Baseline in Fructosamine Levels at Day 8, 15, 22, 29 and 50: Stage 2		Baseline, Day 8, 15, 22, 29 and 50
Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15 and 29: Stage 1		Baseline, Day 8, 15 and 29
Change From Baseline in 1, 5 Anhydroglucitol at Day 8, 15, 22, 29 and 50: Stage 2		Baseline, Day 8, 15, 22, 29 and 50
Number of Participants With Anti-Drug Antibodies (ADA): Stage 1		Day 1 and 29
Number of Participant With Anti-Drug Antibodies (ADA): Stage 2		Day 1, 29 and 50

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2011
• Primary Completion (Actual): December 1, 2011
• Study Completion (Actual): April 1, 2012

Study Registration Dates

• First Submitted: February 9, 2011
• First Submitted That Met QC Criteria: February 21, 2011
• First Posted (Estimate): February 23, 2011

Study Record Updates

• Last Update Posted (Actual): February 9, 2018
• Last Update Submitted That Met QC Criteria: July 28, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Keywords: Type 2 Diabetes; Phase 1; CVX-096
• Additional Relevant MeSH Terms: Diabetes Mellitus; Diabetes Mellitus, Type 2; Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders
• Other Study ID Numbers: B1111002